BRCA1 and neoplasm: Indeed, the analysis of both nature and extent of DDR defects, not limited to BRCA1/2 germline and somatic, deleterious mutations but including a detailed characterization of the tumor mutational signature, is critical for reaching appropriate therapeutic decisions and for patients’ stratification according to the PARPi sensitivity of their tumors.